FDA staff reviewers raised these same evidence gaps during the July 2026 advisory committee hearing, specifically citing insufficient data to support efficacy claims for some proposed uses
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al
Typical session Daily or cycled, per protocol Pricing Book online Choose your treatment and pick a time and place that works for you home, office, or hotel
Conclusion on Procurement: Given the high risk of contamination, mislabeling, and legal ambiguity
Do not freeze the formulation as upon freezing, it lost its efficacy